277 related articles for article (PubMed ID: 26556269)
1. [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].
Holm PS; Retz M; Gschwend JE; Nawroth R
Urologe A; 2016 Mar; 55(3):356-63. PubMed ID: 26556269
[TBL] [Abstract][Full Text] [Related]
2. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
[TBL] [Abstract][Full Text] [Related]
3. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
[TBL] [Abstract][Full Text] [Related]
4. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
[TBL] [Abstract][Full Text] [Related]
5. Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.
Shi J; Fu S; Wang L; Tao Y; Rodriguez R; Wang Z
Anticancer Drugs; 2017 Jan; 28(1):88-96. PubMed ID: 27622605
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS
Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
Yoon AR; Jiao A; Hong J; Kim B; Yun CO
Front Immunol; 2024; 15():1360436. PubMed ID: 38812516
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
10. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
[TBL] [Abstract][Full Text] [Related]
12. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer.
Lichtenegger E; Koll F; Haas H; Mantwill K; Janssen KP; Laschinger M; Gschwend J; Steiger K; Black PC; Moskalev I; Nawroth R; Holm PS
Hum Gene Ther; 2019 Jan; 30(1):44-56. PubMed ID: 29916265
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of oncolytic viruses in China.
Liang M
Curr Pharm Biotechnol; 2012 Jul; 13(9):1852-7. PubMed ID: 21740357
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
16. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
Iizuka K; Shoji K; Fujiyuki T; Moritoh K; Tamura K; Yoshida A; Sato H; Yoneda M; Asano K; Kai C
Res Vet Sci; 2020 Dec; 133():313-317. PubMed ID: 33183781
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses in cancer therapy.
Vähä-Koskela MJ; Heikkilä JE; Hinkkanen AE
Cancer Lett; 2007 Sep; 254(2):178-216. PubMed ID: 17383089
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses in the treatment of cancer: a review of current strategies.
Zeyaullah M; Patro M; Ahmad I; Ibraheem K; Sultan P; Nehal M; Ali A
Pathol Oncol Res; 2012 Oct; 18(4):771-81. PubMed ID: 22714538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]